Man Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-135,546
Closed -$508K 2163
2021
Q4
$508K Sell
135,546
-12,759
-9% -$58.1K ﹤0.01% 1526
2021
Q3
$767K Buy
148,305
+45,437
+44% +$204K ﹤0.01% 1421
2021
Q2
$438K Sell
102,868
-32,344
-24% -$157K ﹤0.01% 1600
2021
Q1
$718K Buy
135,212
+31,740
+31% +$182K ﹤0.01% 1384
2020
Q4
$558K Buy
103,472
+29,819
+40% +$162K ﹤0.01% 1524
2020
Q3
$588K Buy
73,653
+36,498
+98% +$319K ﹤0.01% 1515
2020
Q2
$372K Buy
37,155
+3,333
+10% +$20.9K ﹤0.01% 1512
2020
Q1
$92K Sell
33,822
-1,050,981
-97% -$3.49M ﹤0.01% 1523
2019
Q4
$1.3M Sell
1,084,803
-964,865
-47% -$1.03M ﹤0.01% 1441
2019
Q3
$3.1M Buy
2,049,668
+210,443
+11% +$492K 0.01% 1091
2019
Q2
$7.39M Buy
1,839,225
+500,595
+37% +$2.04M 0.03% 775
2019
Q1
$5.76M Buy
1,338,630
+294,619
+28% +$1.37M 0.02% 841
2018
Q4
$6M Buy
1,044,011
+645,109
+162% +$4.76M 0.03% 681
2018
Q3
$5.41M Buy
+398,902
New +$4.18M 0.02% 947

Other funds holding ADAP